Parallel Advisors, LLC Allakos Inc. Transaction History

Parallel Advisors, LLC

$4.18 Billion
Q3 2024

A detailed history of Parallel Advisors, LLC transactions in Allakos Inc. stock. As of the latest transaction made, Parallel Advisors, LLC holds 770 shares of ALLK stock, worth $977. This represents 0.0% of its overall portfolio holdings.

Number of Shares

770

Previous 770 -0.0%

Holding current value

$977

Previous $0 NaN%

% of portfolio

0.0%

Previous 0.0%

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 08, 2024	SELL	$1.0 - $1.45 $459 - $665	-459 Reduced 37.35%	770 $0
Q4 2023 Feb 09, 2024	SELL	$1.72 - $3.18 $14,805 - $27,373	-8,608 Reduced 87.51%	1,229 $3,000
Q1 2023 May 20, 2024	BUY	$4.3 - $8.27 $37,014 - $71,188	8,608 Added 700.41%	9,837 $43,000
Q1 2023 Apr 25, 2023	BUY	$4.3 - $8.27 $662 - $1,273	154 Added 1.59%	9,837 $43,000
Q4 2022 Feb 03, 2023	BUY	$5.66 - $8.42 $48,721 - $72,479	8,608 Added 800.74%	9,683 $81,000
Q3 2022 Nov 10, 2022	BUY	$3.02 - $6.12 $123 - $250	41 Added 3.97%	1,075 $7,000
Q2 2022 Aug 01, 2022	BUY	$2.6 - $6.14 $686 - $1,620	264 Added 34.29%	1,034 $3,000
Q1 2022 Apr 28, 2022	SELL	$5.08 - $9.81 $243 - $470	-48 Reduced 5.87%	770 $4,000
Q4 2021 Jan 20, 2022	BUY	$8.55 - $111.89 $350 - $4,587	41 Added 5.28%	818 $8,000
Q3 2021 Nov 02, 2021	BUY	$76.53 - $110.43 $535 - $773	7 Added 0.91%	777 $82,000
Q2 2021 Aug 06, 2021	SELL	$85.37 - $114.1 $1,451 - $1,939	-17 Reduced 2.16%	770 $66,000
Q1 2021 Apr 23, 2021	BUY	$109.73 - $153.66 $768 - $1,075	7 Added 0.9%	787 $90,000
Q4 2020 Feb 02, 2021	SELL	$79.58 - $152.45 $27,534 - $52,747	-346 Reduced 30.73%	780 $109,000
Q3 2020 Oct 27, 2020	SELL	$66.43 - $90.99 $3,919 - $5,368	-59 Reduced 4.98%	1,126 $92,000
Q2 2020 Jul 16, 2020	SELL	$44.04 - $80.69 $4,404 - $8,069	-100 Reduced 7.78%	1,185 $85,000
Q1 2020 Apr 27, 2020	BUY	$44.49 - $93.39 $57,169 - $120,006	1,285 New	1,285 $57,000

Others Institutions Holding ALLK

# of Institutions

Shares Held

64.7M

Call Options Held

47.1K

Put Options Held

View Full List

About Allakos Inc.

Ticker ALLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,726,096
Market Cap $108M
Description
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...

More about ALLK

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Parallel Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Parallel Advisors, LLC with notifications on news.

Account

Parallel Advisors, LLC Allakos Inc. Transaction History